Sugi Predict

Sugi Predict / Compounds / SCHEMBL562878

SCHEMBL562878

SCHEMBL562878

Cc1cc(C(F)(F)F)cc(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ HTT P42858 2/20 0.39
▸ GABRB3 P28472 4/20 0.38
▸ GABRA2 P47869 3/20 0.38
▸ GABRB2 P47870 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ NR2E1 Q9Y466 1/20 0.37
▸ GRM5 P41594 1/20 0.36
▸ PHGDH O43175 1/20 0.36
▸ POLQ O75417 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29659055 1.00 HSP90AA1 (0.39) HSP90AA1HSP90AB1HTTGABRB3GABRA2
SCHEMBL29659003 0.85 HTT (0.38) HSP90AA1HSP90AB1HTTNPC1PKM
SCHEMBL22981320 0.85 HTT (0.38) HSP90AA1HSP90AB1HTTNPC1PKM
SCHEMBL561772 0.84 ALDH1A1 (0.40) GABRB3GABRA2GABRB2NPC1RAB9A
SCHEMBL10025587 0.84 HSP90AA1 (0.46) HSP90AA1HSP90AB1HTTGAANPC1
SCHEMBL31039385 0.81 HTT (0.38) HTTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL3186915 0.80 HTT (0.40) HTTGABRB2GAANPC1RAB9A
SCHEMBL3563339 0.77 KIF11 (0.46) NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL31448288 0.77 HSP90AA1 (0.42) HSP90AA1HSP90AB1HTTGAANPC1
SCHEMBL14707739 0.77 HTT (0.38) HTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332156-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-10-30 — — US disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
EP-3870577-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2025-03-19 — — EP disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118852123-A Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same 株式会社大熊制药 2024-10-29 — — CN disclosed
WO-2024219794-A1 SUBSTITUTED ACETYLENE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2024-10-24 — — WO disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
WO-2024182382-A1 4,5-FUSED BICYCLIC PYRROLIDINE AND 4,5-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS CYTEIR THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
CN-118359584-A Dihydropyrazoles and their use 中国药科大学 2024-07-19 — — CN disclosed
EP-0897912-A1 Amidino derivatives useful as nitric oxide synthase inhibitors G.D. SEARLE & CO. (US) 1999-02-24 — — EP disclosed
US-5854234-A Amidino dervatives useful as nitric oxide synthase inhibitors G. D. SEARLE & CO. (US) 1998-12-29 — — US disclosed
CN-1137268-A Amidino derivatives useful as nitric oxide synthase inhibitors SEARLE & CO (US) 1996-12-04 — — CN disclosed
EP-0724570-A1 AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1996-08-07 — — EP disclosed
WO-1995011231-A1 AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G. D. SEARLE & CO. (US) 1995-04-27 — — WO disclosed
US-4898608-A Pyridylthio-acylanilide herbicides BAYER AKTIENGESELLSCHAFT (DE) 1990-02-06 — — US disclosed
EP-0243868-A2 Pyridylthio-acylanilides BAYER AG (DE) 1987-11-04 — — EP disclosed
US-4457927-A Pyrido[2,1-b]quinazolinone derivatives and the preparation and use thereof SCHERING, AKTIENGESELLSCHAFT (DE) 1984-07-03 — — US disclosed
EP-0011142-A1 Pyrido (2,1-b) quinazolinones, their preparation and pharmaceutical compositions containing them SCHERING AKTIENGESELLSCHAFT (DE) 1980-05-28 — — EP disclosed
US-4203988-A ANTISECRETORY AGENTS MERCK & CO., INC. (US) 1980-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332156-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN HSP90AA1 673/4885HSP90AB1 819/4885HTT 375/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HSP90AA1 2667/4885HSP90AB1 2297/4885HTT 1029/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 HSP90AA1 2667/4885HSP90AB1 2297/4885HTT 1029/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 HSP90AA1 1200/4885HSP90AB1 879/4885HTT 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.